Gemini is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its lead candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health. Variations in the gene that encodes CFH strongly correlate with an increased risk of developing AMD. The company is headquartered in Cambridge, MA.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
GEMAYEL GEORGES SEE REMARKS |
|
40,759 | 2021-11-15 | 3 |
|
PIEKOS BRIAN CHIEF FINANCIAL OFFICER |
|
90,720 | 2021-10-18 | 4 |
|
17,245 | 2021-10-04 | 2 | |
|
17,245 | 2021-10-04 | 4 | |
|
17,245 | 2021-10-04 | 2 | |
|
428,745 | 2021-10-04 | 2 | |
|
17,245 | 2021-10-04 | 4 | |
|
MEYENBURG JASON PATRICK PRESIDENT & CEO |
|
13,000 | 2021-05-14 | 3 |
|
STRAPPS WALTER CHIEF SCIENTIFIC OFFICER |
|
9,000 | 2021-04-28 | 4 |
|
BARONE SAMUEL B. CHIEF MEDICAL OFFICER |
|
255,212 | 2021-04-12 | 2 |
|
LAUDER SCOTT CHIEF TECHNOLOGY OFFICER |
|
272,615 | 2021-02-23 | 3 |
|
REDMOND PRECILLIA CHIEF PEOPLE OFFICER |
|
25,489 | 2021-02-23 | 3 |
|
5,826,224 | 2021-02-05 | 1 | |
|
BELOFF GREGG CHIEF FINANCIAL OFFICER |
|
0 | 2021-02-05 | 1 |
|
4,836,106 | 2021-02-05 | 1 | |
|
4,836,106 | 2021-02-05 | 1 | |
|
ATLAS VENTURE ASSOCIATES X, L.P. ATLAS VENTURE ASSOCIATES X, LLC ATLAS VENTURE OPPORTUNITY FUND I, L.P. ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P. ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC |
|
5,254,365 | 2021-02-05 | 1 |
|
FORESITE CAPITAL MANAGEMENT V, LLC |
|
4,870,250 | 2021-02-05 | 1 |
|
UKNIS MARC CHIEF MEDICAL OFFICER |
|
277,117 | 2021-02-05 | 2 |
|
441,500 | 2020-10-19 | 0 | |
|
FORESITE CAPITAL MANAGEMENT V, LLC TANANBAUM JAMES B. PRESIDENT & CEO |
|
441,500 | 2020-08-14 | 1 |
|
0 | 2020-08-11 | 0 | |
|
0 | 2020-08-11 | 0 | |
|
0 | 2020-08-11 | 0 | |
|
0 | 2020-08-11 | 0 | |
|
0 | 2020-08-11 | 0 | |
|
0 | 2020-08-11 | 1 | |
|
RYAN DENNIS D CHIEF FINANCIAL OFFICER |
|
0 | 2020-08-11 | 0 |
|
ROME MICHAEL E VICE PRESIDENT |
|
0 | 2020-08-11 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-16 07:56:41 -0500 | 2021-11-15 | A | 17,245 | a | 17,245 | direct | ||||||||||
| 2021-11-16 07:56:41 -0500 | 2021-11-15 | A | 23,514 | a | 23,514 | direct | ||||||||||
| 2021-10-20 17:49:59 -0400 | 2021-10-18 | A | 90,720 | a | 90,720 | direct |
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 22:15:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 21:45:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 21:15:04 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 20:45:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 20:15:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 19:45:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 19:15:04 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 18:45:04 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 18:15:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 17:45:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 17:15:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 16:45:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 16:15:04 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 15:45:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 15:15:03 UTC | -0.7468 | 0.8168 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 14:45:03 UTC | -0.7201 | 0.7901 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 14:15:05 UTC | -0.7201 | 0.7901 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 13:45:03 UTC | -0.7201 | 0.7901 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 13:15:03 UTC | -0.7201 | 0.7901 | 200000 |
| GEMINI THERAPEUTICS INC GMTX | 2021-12-03 12:45:03 UTC | -0.7201 | 0.7901 | 200000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
